Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Ehab L. Atallah MD

Ehab L. Atallah MD

Associate Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology - Medicine
Program: Hematology

Member of the Cancer Center


  • Incidence and survival of T-cell acute lymphoblastic leukemia in the United States. (Guru Murthy GS, Pondaiah SK, Abedin S, Atallah E) Leuk Lymphoma 2018 Nov 08:1-8 PMID: 30407885 11/09/2018    
  • Incorporating newer agents in the treatment of acute myeloid leukemia. (Raj RV, Abedin SM, Atallah E) Leuk Res 2018 Nov;74:113-120 PMID: 30401522 11/08/2018    
  • Implementation and evaluation of high-dose methotrexate administration guidelines. (Nowak TJ, Lorge AH, Rein LE, Canadeo AM, Frank JP, Samanas LC, Urmanski AM, Atallah EL) J Oncol Pharm Pract 2018 Oct 25:1078155218808866 PMID: 30360674 10/27/2018    
  • Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm. (Guru Murthy GS, Pemmaraju N, Atallah E) Leuk Res 2018 Oct;73:21-23 PMID: 30189324 09/07/2018       1 Citations
  • Amebic Encephalitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy. (Voshtina E, Huang H, Raj R, Atallah E) Case Rep Hematol 2018;2018:6514604 PMID: 30155323 PMCID: PMC6092972 08/30/2018    
  • Incidence and survival of therapy related myeloid neoplasm in United States. (Guru Murthy GS, Hamadani M, Dhakal B, Hari P, Atallah E) Leuk Res 2018 Aug;71:95-99 PMID: 30048839 07/27/2018    
  • Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. (Atallah E, Schiffer CA, Weinfurt KP, Zhang MJ, Radich JP, Oehler VG, Pinilla-Ibarz J, Deininger MWN, Lin L, Larson RA, Mauro MJ, Moore JO, Ritchie EK, Shah NP, Silver RT, Wadleigh M, Cortes J, Thompson J, Guhl J, Horowitz MM, Flynn KE) BMC Cancer 2018 04 02;18(1):359 PMID: 29609532 PMCID: PMC5879565 04/04/2018       1 Citations
  • Early Fluorescence in situ Hybridization Assessment during Acute Myeloid Leukemia Induction Chemotherapy. (Schneidewend R, Hosking P, Brazauskas R, Peterson J, Beaudin C, Michaelis L, Atallah E, Hari P, Carlson K) Acta Haematol 2018;139(3):171-175 PMID: 29597188 03/30/2018    
  • Dasatinib dose management for the treatment of chronic myeloid leukemia. (Talpaz M, Saglio G, Atallah E, Rousselot P) Cancer 2018 Apr 15;124(8):1660-1672 PMID: 29370463 PMCID: PMC5901015 01/26/2018    
  • Will tyrosine kinase inhibitors be part of the treatment armamentarium for CML in the future? (Atallah E, Ritchie E) Expert Opin Pharmacother 2018 02;19(2):79-81 PMID: 29308683 01/09/2018    
  • Chronic Myeloid Leukemia-the Promise of Tyrosine Kinase Inhibitor Discontinuation. (Narra RK, Flynn KE, Atallah E) Curr Hematol Malig Rep 2017 10;12(5):415-423 PMID: 28944397 PMCID: PMC6045428 09/26/2017    
  • Early mortality in patients with acute myelogenous leukemia treated in teaching versus non-teaching hospitals: A large database analysis. (Levin A, Kleman A, Rein L, Tarima S, Michaelis LC, Carlson KS, Hamadani M, Fenske TS, Hari P, Atallah E, Dhakal B) Am J Hematol 2017 Sep;92(9):E563-E565 PMID: 28631379 06/21/2017    
  • Chronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017. (Khoury HJ, Williams LA, Atallah E, Hehlmann R) Am Soc Clin Oncol Educ Book 2017;37:468-479 PMID: 28561719 06/01/2017       4 Citations
  • Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. (Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP) J Clin Oncol 2017 Aug 20;35(24):2745-2753 PMID: 28486043 PMCID: PMC5562170 05/10/2017       45 Citations
  • Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. (Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Guru Murthy GS, Rizzo JD, Saber W, Drobyski W, Michaelis L, Atallah E, Carlson KS, D'Souza A, Fenske TS, Cumpston A, Bunner P, Craig M, Horowitz MM, Hamadani M) Biol Blood Marrow Transplant 2017 Aug;23(8):1295-1302 PMID: 28412518 04/17/2017       3 Citations
  • Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. (Garcia-Manero G, Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, Gaidano G, Scott BL, Greenberg P, Platzbecker U, Steensma DP, Kambhampati S, Kreuzer KA, Godley LA, Atallah E, Collins R Jr, Kantarjian H, Jabbour E, Wilhelm FE, Azarnia N, Silverman LR, ONTIME study investigators) Lancet Oncol 2016 Apr;17(4):496-508 PMID: 26968357 03/13/2016       44 Citations
  • Quality of Life and Long-Term Therapy in Patients with Chronic Myeloid Leukemia. (Flynn KE, Atallah E) Curr Hematol Malig Rep 2016 Apr;11(2):80-5 PMID: 26879546 PMCID: PMC4860261 02/18/2016       10 Citations
  • A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. (Kantarjian HM, Lioure B, Kim SK, Atallah E, Leguay T, Kelly K, Marolleau JP, Escoffre-Barbe M, Thomas XG, Cortes J, Jabbour E, O'Brien S, Bories P, Oprea C, Hatteville L, Dombret H) Clin Lymphoma Myeloma Leuk 2016 Mar;16(3):139-45 PMID: 26775883 PMCID: PMC5557033 01/19/2016       25 Citations
  • Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms. (Hanif A, Hari PN, Atallah E, Carlson KS, Pasquini MC, Michaelis LC) Bone Marrow Transplant 2016 Apr;51(4):617-8 PMID: 26726940 01/05/2016       4 Citations
  • Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis. (Verstovsek S, Atallah E, Mascarenhas J, Sun H, Montgomery M, Gupta V, Mesa R, Gotlib J) Leukemia 2016 06;30(6):1413-5 PMID: 26526986 PMCID: PMC4895165 11/04/2015       1 Citations
  • Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation. (Cornell RF, Zhong X, Arce-Lara C, Atallah E, Blust L, Drobyski WR, Fenske TS, Pasquini MC, Rizzo JD, Saber W, Hari PN) Bone Marrow Transplant 2015 Jul;50(7):914-7 PMID: 25915809 04/29/2015       12 Citations
  • Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I. (Mesa RA, Verstovsek S, Gupta V, Mascarenhas JO, Atallah E, Burn T, Sun W, Sandor V, Gotlib J) Clin Lymphoma Myeloma Leuk 2015 Apr;15(4):214-221.e1 PMID: 25682576 PMCID: PMC4418454 02/16/2015       24 Citations
  • Large granular lymphocytic leukemia presenting late after solid organ transplantation: a case series of four patients and review of the literature. (Kataria A, Cohen E, Saad E, Atallah E, Bresnahan B) Transplant Proc 2014 Dec;46(10):3278-81 PMID: 25240311 09/23/2014       2 Citations
  • Clinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension. (Yan M, Geyer H, Mesa R, Atallah E, Callum J, Bartoszko J, Yee K, Maganti M, Wong F, Gupta V) Clin Lymphoma Myeloma Leuk 2015 Jan;15(1):e1-5 PMID: 25027569 PMCID: PMC4361182 07/17/2014       6 Citations
  • Myelodysplastic syndromes in the United States: an update for clinicians. (Troy JD, Atallah E, Geyer JT, Saber W) Ann Med 2014 Aug;46(5):283-9 PMID: 24716735 04/11/2014       14 Citations
  • Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT). (Atallah E, Bylow K, Troy J, Saber W) Curr Hematol Malig Rep 2014 Mar;9(1):57-65 PMID: 24398726 PMCID: PMC4031643 01/09/2014       11 Citations
  • Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. (Verstovsek S, Gotlib J, Gupta V, Atallah E, Mascarenhas J, Quintas-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian HM, Mesa RA) Onco Targets Ther 2013;7:13-21 PMID: 24368888 PMCID: PMC3869911 12/26/2013    
  • Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. (Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum MH, Karrison T, Erba HP, Green M, Poire X, Koval G, Shannon K, Reddy PL, Joseph L, Atallah EL, Dy P, Thomas SP, Smith SE, Doyle LA, Stadler WM, Larson RA, Stock W, Odenike O) Clin Cancer Res 2014 Jan 15;20(2):490-8 PMID: 24178622 PMCID: PMC4310865 11/02/2013       56 Citations
  • Clarifying the use of ruxolitinib in patients with myelofibrosis. (Kremyanskaya M, Atallah EL, Hoffman R, Mascarenhas JO) Oncology (Williston Park) 2013 Jul;27(7):706-14 PMID: 23977767 08/28/2013       8 Citations
  • Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). (Saber W, Cutler CS, Nakamura R, Zhang MJ, Atallah E, Rizzo JD, Maziarz RT, Cortes J, Kalaycio ME, Horowitz MM) Blood 2013 Sep 12;122(11):1974-82 PMID: 23847196 PMCID: PMC3772501 07/13/2013       44 Citations
  • Emerging drugs for myelofibrosis. (Atallah E, Verstovsek S) Expert Opin Emerg Drugs 2012 Dec;17(4):555-70 PMID: 23186315 PMCID: PMC5009610 11/29/2012       4 Citations
  • Clinical regression of squamous cell carcinoma and keratoacanthomas in a patient treated with a hypomethylating agent. (Randhawa J, Wong S, Atallah E, Olasz E) Int J Dermatol 2014 Jan;53(1):e13-4 PMID: 22998756 09/25/2012       2 Citations
  • Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors. (Randhawa J, Ostojic A, Vrhovac R, Atallah E, Verstovsek S) J Hematol Oncol 2012 Aug 01;5:43 PMID: 22852872 PMCID: PMC3464878 08/03/2012       20 Citations
  • Myeloproliferative neoplasms. (Kim J, Haddad RY, Atallah E) Dis Mon 2012 Apr;58(4):177-94 PMID: 22449367 03/28/2012       5 Citations
  • Chronic myelogenous leukemia for primary care physicians. (Torgerson SR, Haddad RY, Atallah E) Dis Mon 2012 Apr;58(4):168-76 PMID: 22449366 03/28/2012       6 Citations
  • Nilotinib cardiac toxicity: should we still be concerned? (Atallah E) Leuk Res 2011 May;35(5):577-8 PMID: 21333353 02/22/2011       7 Citations
  • Long term follow-up of allogeneic stem cell transplantation in patients with myelodysplastic syndromes using busulfan, cytosine arabinoside, and cyclophosphamide. (Atallah E, Abrams J, Ayash L, Bentley G, Abidi M, Ratanatharathorn V, Uberti J) Am J Hematol 2010 Aug;85(8):579-83 PMID: 20578198 PMCID: PMC3800118 06/26/2010       5 Citations
  • Recurrent deep vein thrombosis and pulmonary embolism in a young man with Klinefelter's syndrome and heterozygous mutation of MTHFR-677C>T and 1298A>C. (Angel JR, Parker S, Sells RE, Atallah E) Blood Coagul Fibrinolysis 2010 Jun;21(4):372-5 PMID: 20449891 05/08/2010       5 Citations
  • Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity. (Bilgi N, Bell K, Ananthakrishnan AN, Atallah E) Ann Pharmacother 2010 May;44(5):926-8 PMID: 20332334 03/25/2010       55 Citations
  • Expression of natural killer receptors in T- and NK-cells: comparison of healthy individuals, patients with prior stem cell transplant, and patients undergoing chemotherapy. (Olteanu H, Schur BC, Bredeson C, Atallah E, Kroft SH) Leuk Lymphoma 2010 Mar;51(3):481-7 PMID: 20141431 02/10/2010       3 Citations
  • Resolution of rheumatoid arthritis symptoms with imatinib mesylate. (Vernon MR, Pearson L, Atallah E) J Clin Rheumatol 2009 Aug;15(5):267 PMID: 19654496 08/06/2009       8 Citations
  • Practical considerations for the management of patients in the tyrosine kinase inhibitor era. (O'Dwyer M, Atallah E) Semin Hematol 2009 Apr;46(2 Suppl 3):S16-21 PMID: 19621545 07/23/2009       9 Citations
  • Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms. (Atallah E, Verstovsek S) Expert Rev Anticancer Ther 2009 May;9(5):663-70 PMID: 19445582 PMCID: PMC5176249 05/19/2009       23 Citations
  • Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors. (Nand R, Bryke C, Kroft SH, Divgi A, Bredeson C, Atallah E) Leuk Res 2009 Aug;33(8):1144-6 PMID: 19394693 04/28/2009       22 Citations
  • Treatment strategies in myelodysplastic syndromes. (Atallah E, Garcia-Manero G) Cancer Invest 2008 Mar;26(2):208-16 PMID: 18259954 02/09/2008       9 Citations
  • Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis. (Atallah E, Nussenzveig R, Yin CC, Bueso-Ramos C, Tam C, Manshouri T, Pierce S, Kantarjian H, Verstovsek S) Leukemia 2008 Jun;22(6):1295-8 PMID: 18059483 12/07/2007       22 Citations
  • Use of hypomethylating agents in myelodysplastic syndromes. (Atallah E, Garcia-Manero G) Clin Adv Hematol Oncol 2007 Jul;5(7):544-52 PMID: 17679928 08/08/2007       6 Citations
  • Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. (Atallah E, Cortes J, O'Brien S, Pierce S, Rios MB, Estey E, Markman M, Keating M, Freireich EJ, Kantarjian H) Blood 2007 Nov 15;110(10):3547-51 PMID: 17673605 08/04/2007       42 Citations
  • Congestive heart failure is a rare event in patients receiving imatinib therapy. (Atallah E, Durand JB, Kantarjian H, Cortes J) Blood 2007 Aug 15;110(4):1233-7 PMID: 17449798 04/24/2007       181 Citations
  • Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors. (Atallah E, Kantarjian H, Cortes J) Clin Lymphoma Myeloma 2007 Mar;7 Suppl 3:S105-12 PMID: 17382019 03/27/2007       23 Citations
  • Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase. (Atallah E, Cortes J) Curr Opin Hematol 2007 Mar;14(2):138-44 PMID: 17255791 01/27/2007       3 Citations
  • In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. (Atallah E, Kantarjian H, Cortes J) Nat Med 2007 Jan;13(1):14; author reply 15-6 PMID: 17206119 01/09/2007       29 Citations
  • The role of decitabine in the treatment of myelodysplastic syndromes. (Atallah E, Kantarjian H, Garcia-Manero G) Expert Opin Pharmacother 2007 Jan;8(1):65-73 PMID: 17163808 12/14/2006       19 Citations
  • Agent Orange, prostate cancer irradiation and acute promyelocyic leukemia (APL): is there a link? (Atallah E, Schiffer CA) Leuk Res 2007 May;31(5):720-1 PMID: 16956658 09/08/2006       2 Citations
  • Granulocyte transfusion. (Atallah E, Schiffer CA) Curr Opin Hematol 2006 Jan;13(1):45-9 PMID: 16319687 12/02/2005       31 Citations
  • Treatment of metastatic malignant melanoma. (Atallah E, Flaherty L) Curr Treat Options Oncol 2005 May;6(3):185-93 PMID: 15869730 05/05/2005       141 Citations
  • Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy. (Atallah E, Talpaz M, O'brien S, Rios MB, Guo JQ, Arlinghaus R, Fernandes-Reese S, Kantarjian H) Cancer 2002 Jun 01;94(11):2996-9 PMID: 12115389 07/13/2002       15 Citations
  • [Experimental and clinical studies on the correlation between periodontal disease and diabetes, cirrhosis, hepatic steatosis and low gastric acidity]. (Sarnowska I) Czas Stomatol 1985 Aug;38(8):547-50 PMID: 3869911 08/01/1985    
  • Last update: 01/02/2019
    jenkins-FCD Prod-310 bff9d975ec7f2d302586822146c2801dd4449aad